• 1984 BSc (2:1), University of London, in basic medical science with physiology
• 1987 MB BS degrees awarded by Charing Cross & Westminster Medical School
• 1990 Membership of Royal College of Physicians of London
• 1995 Doctor of Medicine, University of London. Thesis entitled “The effect of Helicobacter pylori infection on gastric acid secretion and duodenal bulb morphology”.
• 2001 Fellowship of Royal College of Physicians of London
• 2010 Post Graduate Certificate In Strategic Leadership

• Kent, Sussex and Surrey Representative on the British Society of Gastroenterology Independent Practice Committee (2016-)
• Chair of Clinical Services & Standards Committee, British Society of Gastroenterology (2012-14)
• Deputy Chair of Clinical Services & Standards Committee, British Society of Gastroenterology (2009-12)
• NICE Ulcerative Colitis Guideline Development Group (2011-12)
• British Society of Gastroenterology Lead for Revalidation (2009-14)
• Chair, British Society of Gastroenterology Independent Practice Committee (2009-11)
• Honorary Secretary to British Society of Gastroenterology (2005-9)
• Clinical Lead for Inflammatory Bowel Disease, The Tunbridge Wells Hospital
• Divisional Director, Planned Care Services, Maidstone and Tunbridge Wells NHS Trust (2010-11)
• Clinical Lead for Endoscopy for South East Coast Strategic Health Authority (2005-8)

Adam attended Charing Cross and Westminster Medical School, London from 1981 until graduation in 1987. His post-graduate training in internal medicine and gastroenterology took place in Charing Cross, St Mary’s, Central Middlesex, St. Thomas and St. George’s Hospitals in London and in Kingston, Epsom, Hillingdon and Harefield Hospitals in the Home Counties.

Adam then spent two years (1993-5) in full time academic study as a research fellow investigating the relationship between infection with Helicobacter pylori, gastric acid output, duodenal bulb morphology and duodenal ulcer disease. This work was submitted as a thesis to the University of London leading to Doctor of Medicine higher degree.

From 1995 until 1997 Adam worked as Senior Registrar to Dr JJ Misiewicz and Professor D Silk at Central Middlesex Hospital, London. He completed his clinical training in dyspepsia, gastro-oesophageal reflux and liver diseases and developed particular expertise in the management of patients with inflammatory bowel diseases and functional abdominal conditions, such as irritable bowel syndrome.

Adam was appointed as Consultant Physician & Gastroenterologist to Kent & Sussex Hospital in spring 1997, and maintained this full-time position at the Tunbridge Wells Hospital until October 2017.

ORIGINAL PAPERS

 Moayyedi P, on behalf of the Dyspepsia Review Group.

Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia

BMJ 2000; 321: 659-664.

Moayyedi P, Soo S, Deeks J, Delaney B, Harris AW, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D.

Eradication of Helicobacter pylori for non-ulcer dyspepsia

Cochrane Database Systematic Reviews 2000; (2): CD 2096.

Moayyedi P, Soo S, Deeks J, Forman D, Harris AW, Innes M, Delaney B.

Systematic review: antacids H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia

Aliment Pharmacol Ther 2003: 17: 1215-1227

Hayee BH, Harris AW

Methotrexate for Crohn’s disease: experience in a district general hospital

Eur J Gastroenterol Hepatol 2005; 17 (9): 893-898

Russo EA, Harris AW, Campbell S, et al

Experience of maintenance infliximab therapy for refractory ulcerative colitis in England

Aliment Pharmacol Ther 2009; 29: 308-314

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart AL, Hamlin J, Orchard J, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O’Connor M, Harris AW, O’Morain C, Ghosh S.

Survey regarding the use of adalimumab as maintenance therapy in Crohn’s disease in UK

Eur J Gastroenterol Hepatol 2010; 22 (3):334-9

Coltart I, Blackmore L, Casley J, Harris AW.

Parenteral methotrexate for patients with Crohn’s disease: how to develop a high-quality and safe self-administration service

Frontline Gastroenterology 2012; 3: 36-39.

Blackmore L, Harris AW

A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn’s disease: how will NICE guidance affect patient care?

Clinical Medicine 2012; 12(3): 235-8.

NICE Clinical Guideline (166) on the Management of Ulcerative Colitis. June 2013

http://guidance.nice.org.uk/CG166

Saifuddin MA, Harris AW.

Tacrolimus therapy in moderate to sub-acute ulcerative proctocolitis: a large single centre cohort study

Frontline Gastroenterology 2018; 9:148-153

REVIEWS

AW Harris

Treatment of H pylori

World Journal of Gastroenterology 2001; 7 (3): 303-307

Adam Harris, JJ Misiewicz

Management of Helicobacter pylori infection

British Medical Journal 2001; 323: 1047-50

GSZ Tun, AW Harris, AJ Lobo

Ulcerative colitis: Management in adults, children, and young people – concise guidance.

Clinical Medicine 2017; 17 (5): 1-5

BOOKS

Eds: Baron JH, Logan R, Harris AW, Misiewicz JJ.

ABC of Upper Gastrointestinal Tract

, 2002 (ISBN 0-7279-1266-6)